Flexion Therapeutics, Inc. (NASDAQ:FLXN) Files An 8-K Results of Operations and Financial Condition

0
Flexion Therapeutics, Inc. (NASDAQ:FLXN) Files An 8-K Results of Operations and Financial Condition

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Results of Operations and Financial Condition.

On January 3, 2019, Flexion Therapeutics, Inc. issued a press release announcing its preliminary unaudited financial results for the fourth quarter and year ended December 31, 2018. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

Flexion Therapeutics Inc Exhibit
EX-99.1 2 flxn-ex991_6.htm EX-99.1 flxn-ex991_6.htm EXHIBIT 99.1   Flexion Therapeutics Announces Preliminary,…
To view the full exhibit click here

About Flexion Therapeutics, Inc. (NASDAQ:FLXN)

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.